

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

Boulogne-Billancourt (France), July 10, 2020 – Under the liquidity agreement entrusted by IPSEN to NATIXIS ODDO BHF, as of June 30, 2020, the following resources were included to the dedicated liquidity account:

- 16,892 shares
- €2,515,229.70

It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account:

- 12,751 shares
- €3,137,934.80

Between January 2, 2020 and June 30, 2020 have been executed:

- 1,428 purchase transactions
- 1,369 sell transactions

Under the same period, the volumes traded represented:

- 221,762 shares and €14,321,430.90 to the purchase
- 233,938 shares and €15,216,880.90 to the sell

About Ipsen

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.5 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipсен.com.

For further information:

Media

Christian Marcoux

Senior Vice President, Global Communications
+33 (0)1 58 33 67 94
christian.marcoux@ipsen.com

Fanny Allaire

Director, Ipsen France Hub, Global Communications
+33 (0) 1 58 33 58 96
fanny.allaire@ipsen.com

Financial Community

Eugenia Litz

Vice President, Investor Relations
+44 (0) 1753 627721
eugenia.litz@ipsen.com

Myriam Koutchinsky

Investor Relations Manager
+33 (0)1 58 33 51 04
myriam.koutchinsky@ipsen.com